Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study.
chronic kidney disease
dialysis
erythroferrone
iron
mortality
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Apr 2019
16 Apr 2019
Historique:
received:
07
03
2019
revised:
05
04
2019
accepted:
05
04
2019
entrez:
19
4
2019
pubmed:
19
4
2019
medline:
19
4
2019
Statut:
epublish
Résumé
Erythroferrone (ERFE) is a hepcidin inhibitor whose synthesis is stimulated by erythropoietin, which increases iron absorption and mobilization. We studied the association between serum ERFE and mortality and non-fatal cardiovascular (CV) events in a cohort of 1123 hemodialysis patients and in a cohort of 745 stage 1-5 chronic kidney disease (CKD) patients. Erythroferrone was measured by a validated enzyme-linked immunosorbent assay (ELISA). In the hemodialysis cohort, serum ERFE associated directly with erythropoiesis stimulating agents (ESA) dose (
Identifiants
pubmed: 30995819
pii: jcm8040523
doi: 10.3390/jcm8040523
pmc: PMC6518296
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
Conflict of Interest: The authors B.S., P.P., C.T., G.T., F.M., and C.Z. declare no conflict of interest. R.K., L.L., and M.D. are all employees of Corvidia Therapeutics. Corvidia is interested in the mechanisms of EPO-linked CV risk and whether reducing EPO exposure may reduce that risk but has no interest in ERFE as a commercial entity.
Références
J Am Soc Nephrol. 2001 Jul;12(7):1508-15
pubmed: 11423580
Arch Intern Med. 2002 Jun 24;162(12):1401-8
pubmed: 12076240
Am J Kidney Dis. 2005 Oct;46(4):610-20
pubmed: 16183415
Kidney Int. 2006 Jul;70(1):26-33
pubmed: 16723985
Am J Kidney Dis. 2007 Sep;50(3):471-530
pubmed: 17720528
Am J Physiol Renal Physiol. 2008 Jan;294(1):F1-9
pubmed: 17928410
Ann Intern Med. 2010 Jul 6;153(1):23-33
pubmed: 20439566
Adv Pharmacol. 2010;60:257-85
pubmed: 21081221
J Biol Chem. 2012 Apr 6;287(15):11968-80
pubmed: 22351773
Nephrol Dial Transplant. 2013 Dec;28(12):3062-71
pubmed: 23147161
J Nephrol. 2012 Nov-Dec;25(6):1081-90
pubmed: 23172127
Lancet. 2013 Jul 27;382(9889):339-52
pubmed: 23727170
Nephrol Dial Transplant. 2014 Feb;29(2):263-73
pubmed: 24235084
Kidney Int. 2014 Oct;86(4):845-54
pubmed: 24759150
J Res Med Sci. 2014 Feb;19(2):164-74
pubmed: 24778671
Nat Genet. 2014 Jul;46(7):678-84
pubmed: 24880340
Am J Nephrol. 2014;39(6):536-42
pubmed: 24943037
Blood. 2014 Oct 16;124(16):2569-74
pubmed: 25193872
Am J Nephrol. 2014;40(6):561-70
pubmed: 25592750
Biosci Rep. 2015 Mar 31;35(3):null
pubmed: 26182354
PLoS One. 2016 Mar 15;11(3):e0151601
pubmed: 26978524
Semin Nephrol. 2016 Jul;36(4):252-61
pubmed: 27475656
Int J Cardiol. 2017 Jul 1;238:151-158
pubmed: 28341375
Blood. 2017 Sep 7;130(10):1243-1246
pubmed: 28739636
Haematologica. 2018 Apr;103(4):e141-e142
pubmed: 29419424
Circ Res. 2018 Dec 7;123(12):1326-1338
pubmed: 30566056
Circ Res. 2018 Dec 7;123(12):1264-1266
pubmed: 30566057